Treatment with the NR2F2 inhibitor CIA1 blocks NR2F2 activation of BGN, reducing BGN expression and AKT pathway activity, inhibiting malignant behavior of tumor cells, and reversing macrophage polarization, thereby restoring antitumor immunity. The gene discussed is AKT1; the disease is neoplasm.